SlideShare a Scribd company logo
Interventions to  Improve Quality of Care Luigi Meneghini, MD, MBA Diabetes Research Institute (DRI) University of Miami School of Medicine II PAHO-DOTA Workshop on Quality of Diabetes Care DRI, 14–16 May 2003
Outline ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Purpose of Optimizing Care ,[object Object],[object Object],[object Object],[object Object],[object Object]
Macro & Micro-Vascular Endpoints   Source:  Stratton IM et al. for the  UK Prospective Diabetes Study Group.  UKPDS 35.  BMJ  2000; 321: 405–412. ,[object Object],[object Object],Updated mean hemoglobin A 1c  concentration (%) 80 60 40 20 0 5 6 7 8 9 10 11 Adjusted* incidence  per 1000 person-years (%) Myocardial infarction Microvascular end points
Mastering Your Diabetes   Metabolic & Psychosocial Outcomes Diabetes Empowerment Scale (DES) The DES is a valid and reliable survey of patient empowerment which yields an overall empowerment score based on all 28 items and three subscale scores (range for all scales: 1.0-5.0).  Improvement was evident on all DES scales for participants in the  MYD  pilot study, despite high baseline values. Diabetes Empowerment Scale   Pretest   Posttest   3mF/U Overall empowerment   4.1  4.2   4.3* Managing psychosocial aspects  3.9  4.2   4.2 Dissatisfaction/readiness to change 4.3  4.5   4.6* Setting/ achieving diabetes goals 4.0  4.0   4.1 (*P<0.05 v. baseline) Quality of Life & Self-Efficacy Measures of both Quality of Life (QOL) and Self-Efficacy showed statistically significant improvement following the intervention.  At the three month follow-up the most significant improvement in QOL sub-scales was for Satisfaction (p=0.0113).   8.84 8.01 7.65 8.10 7.50 6.80 7.00 7.20 7.40 7.60 7.80 8.00 8.20 8.40 8.60 8.80 Mean HbA1c % Mo 1-3 Pre-MYD * p<0.05 v. pre-MYD Mo 4-6 Mo 7-9 Mo 10-12 * * *
Healthcare Costs Increase With Worsening Glycemic Control *In patients with  Type 2 diabetes alone (no cardiovascular complications). Increase in medical costs associated with rising HbA 1c  levels compared to costs for patients with HbA 1c  of 6%* 3-Year Medical Costs,  1993–1995 ($) 12,000 10,000 9,000 8,000 6 7 8 9 10 Baseline HbA 1c  (%), 1992 5% 11% 21% 36% 11,000 Source:  Gilmer TP et al.  Diabetes Care  1997; 20: 1847-1853.
Increase of Diabetes & Gestational Diabetes in the USA
Global  Projections of Diabetes   (in millions, 1995-2010) 13.0 17.5 35% 12.4 22.5 81% 22.0 32.9 50% 0.9 1.3 44% 7.3 14.1 93% World 1995 = 118 million 2010 = 221 million Increase of 87% 62.8 132.3 111%
Diabetes Mellitus in the USA:   Health Impact of the Disease Diabetes Blindness* Kidney   failure* Amputation* Life expectancy reduced by 5–10 years Heart disease ­ 2X to 4X *Diabetes is the #1 cause of renal failure,    new cases of blindness, and   non-traumatic amputations. Nerve damage in  60% to 70% of patients 6th leading cause of death  Sources: Diabetes Statistics . October 1995  (updated 1997). NIDDK publication NIH 96-3926.  Harris, MI. In:  Diabetes in America ( 2nd ed.)  1995: 1-13.
The Cost of Diabetes Diabetes costs the United States ~$132 billion annually! Total = $91.8 Billion Total = $39.8 Billion Source:  American Diabetes Association.  Diabetes Care  2003; 26: 917-932. $44.1 $23.2 $24.6 Direct Medical Expenses General Medical Conditions Diabetes & Acute Metabolic Complications Chronic Diabetes Complications Indirect Medical Expenses $21.6 $7.5 $10.8 Mortality Lost work days Restricted activity Permanent disability
Projected Costs of Diabetes  (USA, in billions) $200 $100 $0 1997 2002 2010 2020 $98 $192 $156 $132
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],*Some patients had more than 1 complication at diagnosis † Prevalence of each individual condition UKPDS Group.  Diabetologia  1991;34:877-890. Prevalence of Complications at Time of Diagnosis
Percentage of Adults with  Type 2 Diabetes by HbA 1c  Level % of Subjects Source:  Harris MI et al.  Diabetes Care  1999; 22: 403-408. NHANES III (1988–1994) 0% 20% 40% 60% 80% 100% Oral Insulin All >9% 8%–9% 7%–8% <7% 38% 27% 45% 20% 15% 27% 22% 19% 32% 18% 14% 23% ,[object Object],HbA 1c
Metabolic Goals to  Reduce Illness ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Blood Glucose ,[object Object],[object Object],[object Object]
 
NCQA/ADA Diabetes Physician Recognition Program 
NCQA/ADA Diabetes Physician Recognition Program 
Recognized Physicians Provide High-Quality Care Physicians achieving Recognition through the NCQA/ADA Diabetes Provider Recognition Program (DPRP) % of patients with Diabetes Provider Recognition Program, average    performance of applicants, 2001 data. Health plan average, 2000 average performance data for    plans, as reported in NCQA’s  The State of Managed    Care Quality - 2001  report, pp. 46 - 47. Medicare, 1998-99 fee-for-service data for the median state,   JAMA,10/4/00 , Vol. 284, No. 13, p. 1674.  * Lower is better for this measure.
Measurement Leads to Improvement ,[object Object],[object Object],[object Object],[object Object]
Short-Term Economic Impact of  Managing Diabetes Is there a financial incentive for insurance plans and governments?
Incremental Cost/QALY Gained  When Compared to Standard Care Source:  Leroith (ed.)  Diabetes Mellitus , 1996, pp. 621-630.
Excess Costs for Patients with Diabetes in a MCO ,[object Object],[object Object],[object Object],[object Object],Source:  Selby JV.  Diabetes Care  1997; 9: 1396.
Yearly Costs of Care for Members  with and without Diabetes Source:  Selby JV.  Diabetes Care  1997; 9: 1396.
Excess Cost of Care for Diabetes  (by site of care) Source:  Selby JV.  Diabetes Care  1997; 9: 1396.
Standardized Cost Differential for  1% Change in HbA1c Source:  Gilmer TP et al.  Diabetes Care  1997;20:1847-1853.
Impact of Comprehensive Diabetes Management Program ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Rubin RJ, et al.  J Clin Endocrinol Metab 1998; 83: 2635
Impact of Comprehensive  Diabetes Management Program Source:  Rubin RJ, et al.    J Clin Endocrinol Metab  1998; 83: 2635. * Total costs decreased by $44 per member/month (10.9%) which would translate into savings of $528,000 in the first year for a plan with 1000 members with diabetes.  Break-even at 1,265 members with diabetes as per DTCA.  $406 $362 $182 $135 $84 $76 $44 $45 $66 $76 $29 $30 $0 $50 $100 $150 $200 $250 $300 $350 $400 $450 Average Cost per member/month Total Inpatient Outpatient MD Drugs Other Baseline (54,186 member months) Follow-up (55,879 member months)
Approach to  Insulin-Requiring Patients with Type 2 Diabetes
Physiologic Insulin Replacement The Basal/Bolus Approach ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Identifying the Glycemic Burden Fasting Pre-prandial Post-prandial Hepatic Glucose Output Glucose   Disposal Prandial Insulin Secretion
Indications for Insulin Therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Physiology of Insulin Secretion Muscle Gut Liver Hepatic Glucose Output Intestinal CHO Absorption Plasma Glucose  Basal insulin Bolus Insulin (-) Pancreas
4:00 25 50 75 16:00 20:00  24:00 4:00 Plasma Insulin  µ U/ml)  8:00 12:00 8:00 Time Near-Physiologic Insulin Replacement Lispro Aspart Regular Ultralente Glargine CSII Prandial replacement Basal Replacement
Translating the  Basal/Bolus Prescription PCP Carbohydrate counting Correction (supplemental) scale Insulin algorithms Insulin administration Glucose monitoring Psychosocial issues Special situation adjustments Diabetes Overview Knowledge & skills assessment Prandial insulin coverage Insulin  Prescription Lantus 20 u HS CHO ratio 1/10 Correction ratio 1/40 BG target 120 mg/dl ?
Components of the Diabetes Team   The Ideal Scenario Dietitian Endocrinologist Nurse Educator Exercise Therapist Case Manager PCP            
 
Success of Program Depends on ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The End                                         
Calculating Insulin Ratio & Doses ,[object Object],[object Object],[object Object],[object Object],[object Object]
Calculating Insulin Ratio & Doses ,[object Object],[object Object],[object Object],[object Object]
Basal/Bolus Insulin Prescription ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

Insulin Initiation : When We should Start with Basal Insulin?
Insulin Initiation : When We should Start with Basal Insulin?Insulin Initiation : When We should Start with Basal Insulin?
Insulin Initiation : When We should Start with Basal Insulin?
mataharitimoer MT
 
sitagliptin for diabetics
sitagliptin for diabeticssitagliptin for diabetics
sitagliptin for diabetics
Mahmoud Yossof
 
GLP1 Role : DM type 2
GLP1 Role : DM type 2GLP1 Role : DM type 2
GLP1 Role : DM type 2
Mohammad Othman Daoud
 
Cardiorenal syndrome prof.osama el-shahat
Cardiorenal syndrome   prof.osama el-shahatCardiorenal syndrome   prof.osama el-shahat
Cardiorenal syndrome prof.osama el-shahat
FarragBahbah
 
SGLT2 inhibitors
SGLT2 inhibitorsSGLT2 inhibitors
SGLT2 inhibitors
AhmedElBorae1
 
Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...
Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...
Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...
vaibhavyawalkar
 
ADA 2022.pptx
ADA 2022.pptxADA 2022.pptx
ADA 2022.pptx
AnhPhan285568
 
SGLT2 inhibitor trials
SGLT2 inhibitor trialsSGLT2 inhibitor trials
SGLT2 inhibitor trials
Dr. Rohan Sonawane
 
Dpp4i vs sglt2 inhibitors against the motion
Dpp4i vs sglt2 inhibitors  against the motionDpp4i vs sglt2 inhibitors  against the motion
Dpp4i vs sglt2 inhibitors against the motion
Sujoy Majumdar
 
PARADIGM HF TRIAL
PARADIGM HF TRIALPARADIGM HF TRIAL
PARADIGM HF TRIAL
Praveen Nagula
 
CARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKD
CARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKDCARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKD
CARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKD
Mohd Tariq Ali
 
SGLT2I The paradigm change in diabetes management
SGLT2I The paradigm change in diabetes managementSGLT2I The paradigm change in diabetes management
SGLT2I The paradigm change in diabetes management
Praveen Nagula
 
Prevention of type 2 diabetes
Prevention of type 2 diabetesPrevention of type 2 diabetes
Prevention of type 2 diabetes
Mohamed BADR
 
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsThe Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsPHAM HUU THAI
 
Recent advancement in managing diabetic nephropathy
Recent advancement in managing diabetic nephropathyRecent advancement in managing diabetic nephropathy
Recent advancement in managing diabetic nephropathy
pp_shivgunde
 
CKD and Diabetes: Tips & Tricks
CKD and Diabetes: Tips & TricksCKD and Diabetes: Tips & Tricks
CKD and Diabetes: Tips & Tricks
Usama Ragab
 
Hypertension and ramadan
Hypertension and ramadanHypertension and ramadan
Hypertension and ramadan
A.Salam Sharif
 
Empagliflozin and Cardiovascular Outcomes
Empagliflozin and Cardiovascular OutcomesEmpagliflozin and Cardiovascular Outcomes
Empagliflozin and Cardiovascular OutcomesUyen Nguyen
 
Diabetes and heart two sides of the same coin
Diabetes and heart two sides of the same coinDiabetes and heart two sides of the same coin
Diabetes and heart two sides of the same coin
Sunil Wadhwa
 
Prof. megahed abo el magd presentation
Prof. megahed abo el magd presentationProf. megahed abo el magd presentation
Prof. megahed abo el magd presentation
FarragBahbah
 

What's hot (20)

Insulin Initiation : When We should Start with Basal Insulin?
Insulin Initiation : When We should Start with Basal Insulin?Insulin Initiation : When We should Start with Basal Insulin?
Insulin Initiation : When We should Start with Basal Insulin?
 
sitagliptin for diabetics
sitagliptin for diabeticssitagliptin for diabetics
sitagliptin for diabetics
 
GLP1 Role : DM type 2
GLP1 Role : DM type 2GLP1 Role : DM type 2
GLP1 Role : DM type 2
 
Cardiorenal syndrome prof.osama el-shahat
Cardiorenal syndrome   prof.osama el-shahatCardiorenal syndrome   prof.osama el-shahat
Cardiorenal syndrome prof.osama el-shahat
 
SGLT2 inhibitors
SGLT2 inhibitorsSGLT2 inhibitors
SGLT2 inhibitors
 
Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...
Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...
Newer trends in heart failure by Dr. Vaibhav Yawalkar MD DM Cardiology, Consu...
 
ADA 2022.pptx
ADA 2022.pptxADA 2022.pptx
ADA 2022.pptx
 
SGLT2 inhibitor trials
SGLT2 inhibitor trialsSGLT2 inhibitor trials
SGLT2 inhibitor trials
 
Dpp4i vs sglt2 inhibitors against the motion
Dpp4i vs sglt2 inhibitors  against the motionDpp4i vs sglt2 inhibitors  against the motion
Dpp4i vs sglt2 inhibitors against the motion
 
PARADIGM HF TRIAL
PARADIGM HF TRIALPARADIGM HF TRIAL
PARADIGM HF TRIAL
 
CARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKD
CARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKDCARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKD
CARDIAC COMPLICATIONS & ITS MANAGEMENT OF CKD
 
SGLT2I The paradigm change in diabetes management
SGLT2I The paradigm change in diabetes managementSGLT2I The paradigm change in diabetes management
SGLT2I The paradigm change in diabetes management
 
Prevention of type 2 diabetes
Prevention of type 2 diabetesPrevention of type 2 diabetes
Prevention of type 2 diabetes
 
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 InhibitorsThe Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
The Role of SGLT 2 Inhibitors and GLP 1 Receptor Agonists and DPP 4 Inhibitors
 
Recent advancement in managing diabetic nephropathy
Recent advancement in managing diabetic nephropathyRecent advancement in managing diabetic nephropathy
Recent advancement in managing diabetic nephropathy
 
CKD and Diabetes: Tips & Tricks
CKD and Diabetes: Tips & TricksCKD and Diabetes: Tips & Tricks
CKD and Diabetes: Tips & Tricks
 
Hypertension and ramadan
Hypertension and ramadanHypertension and ramadan
Hypertension and ramadan
 
Empagliflozin and Cardiovascular Outcomes
Empagliflozin and Cardiovascular OutcomesEmpagliflozin and Cardiovascular Outcomes
Empagliflozin and Cardiovascular Outcomes
 
Diabetes and heart two sides of the same coin
Diabetes and heart two sides of the same coinDiabetes and heart two sides of the same coin
Diabetes and heart two sides of the same coin
 
Prof. megahed abo el magd presentation
Prof. megahed abo el magd presentationProf. megahed abo el magd presentation
Prof. megahed abo el magd presentation
 

Similar to Managing Type 2 Diabetes

ueda2013 dpp-4 inhibitors “vildagliptin” -d.mesbah
ueda2013 dpp-4 inhibitors “vildagliptin” -d.mesbahueda2013 dpp-4 inhibitors “vildagliptin” -d.mesbah
ueda2013 dpp-4 inhibitors “vildagliptin” -d.mesbah
ueda2015
 
T1D-S4-Treatment.051217.pdf
T1D-S4-Treatment.051217.pdfT1D-S4-Treatment.051217.pdf
T1D-S4-Treatment.051217.pdf
AliEllaffi
 
PSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptx
PSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptxPSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptx
PSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptx
Rhoda Isip
 
Futuro en el tratamiento de la DM2
Futuro en el tratamiento de la DM2Futuro en el tratamiento de la DM2
Futuro en el tratamiento de la DM2
Conferencia Sindrome Metabolico
 
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...Vishal Saundankar MS, PGDMM, BS (PHARMACY)
 
Nutrition therapy work shop dawly first part 2017
Nutrition therapy work shop dawly   first part  2017Nutrition therapy work shop dawly   first part  2017
Nutrition therapy work shop dawly first part 2017
FarragBahbah
 
Ueda2015 sanofi insulin therapy dr.khaled el-hadidy
Ueda2015 sanofi insulin therapy dr.khaled el-hadidyUeda2015 sanofi insulin therapy dr.khaled el-hadidy
Ueda2015 sanofi insulin therapy dr.khaled el-hadidyueda2015
 
Updates of Diabetes Management 2020- Dr Shahjada Selim
Updates of Diabetes Management 2020- Dr Shahjada SelimUpdates of Diabetes Management 2020- Dr Shahjada Selim
Updates of Diabetes Management 2020- Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Diabetes atlas key headlines 2012
Diabetes atlas   key headlines 2012Diabetes atlas   key headlines 2012
Diabetes atlas key headlines 2012rightcare
 
Public heath challenges for NCDs, UHC and cost effective treatment, MySPOR 2014
Public heath challenges for NCDs, UHC and cost effective treatment, MySPOR 2014Public heath challenges for NCDs, UHC and cost effective treatment, MySPOR 2014
Public heath challenges for NCDs, UHC and cost effective treatment, MySPOR 2014
Feisul Mustapha
 
Improved Outcomes from Diabetes Outreach Programs in Rural and Remote Aborigi...
Improved Outcomes from Diabetes Outreach Programs in Rural and Remote Aborigi...Improved Outcomes from Diabetes Outreach Programs in Rural and Remote Aborigi...
Improved Outcomes from Diabetes Outreach Programs in Rural and Remote Aborigi...
Kelli Buckreus
 
ueda2012 cost effective diabetes treatment-d.edwin
ueda2012 cost effective diabetes treatment-d.edwinueda2012 cost effective diabetes treatment-d.edwin
ueda2012 cost effective diabetes treatment-d.edwin
ueda2015
 
Materi Workshop Diabetes Melitus untuk Dokter Umum - Practical Management of ...
Materi Workshop Diabetes Melitus untuk Dokter Umum - Practical Management of ...Materi Workshop Diabetes Melitus untuk Dokter Umum - Practical Management of ...
Materi Workshop Diabetes Melitus untuk Dokter Umum - Practical Management of ...
Dayu Agung Dewi Sawitri
 
Clinical Improvement Proceeds Glycemic Homeostasis After Duodenal-jejunal Byp...
Clinical Improvement Proceeds Glycemic Homeostasis After Duodenal-jejunal Byp...Clinical Improvement Proceeds Glycemic Homeostasis After Duodenal-jejunal Byp...
Clinical Improvement Proceeds Glycemic Homeostasis After Duodenal-jejunal Byp...George S. Ferzli
 
Prof-Dennis-Yue-Kellion-Lecture.ppt
Prof-Dennis-Yue-Kellion-Lecture.pptProf-Dennis-Yue-Kellion-Lecture.ppt
Prof-Dennis-Yue-Kellion-Lecture.ppt
victorgolubev97
 
Renal disease in diabetes from prediabetes to late vasculopathy complication...
Renal disease in diabetes from prediabetes  to late vasculopathy complication...Renal disease in diabetes from prediabetes  to late vasculopathy complication...
Renal disease in diabetes from prediabetes to late vasculopathy complication...
nephro mih
 
What Spine Surgeons Need to Know About Dietary Strategies for Heart Disease a...
What Spine Surgeons Need to Know About Dietary Strategies for Heart Disease a...What Spine Surgeons Need to Know About Dietary Strategies for Heart Disease a...
What Spine Surgeons Need to Know About Dietary Strategies for Heart Disease a...
James McCarter
 
Resiko metabolik
Resiko metabolik Resiko metabolik
Resiko metabolik
Ronald David Martua
 
Modern therapy in diabetics with cad scintic day
Modern therapy in diabetics  with cad scintic dayModern therapy in diabetics  with cad scintic day
Modern therapy in diabetics with cad scintic day
Osama Almaraghi
 

Similar to Managing Type 2 Diabetes (20)

ueda2013 dpp-4 inhibitors “vildagliptin” -d.mesbah
ueda2013 dpp-4 inhibitors “vildagliptin” -d.mesbahueda2013 dpp-4 inhibitors “vildagliptin” -d.mesbah
ueda2013 dpp-4 inhibitors “vildagliptin” -d.mesbah
 
T1D-S4-Treatment.051217.pdf
T1D-S4-Treatment.051217.pdfT1D-S4-Treatment.051217.pdf
T1D-S4-Treatment.051217.pdf
 
PSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptx
PSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptxPSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptx
PSEDM-DOH WorkshopDiabetes Management Training Using Insulin v_7 - 20170321.pptx
 
Futuro en el tratamiento de la DM2
Futuro en el tratamiento de la DM2Futuro en el tratamiento de la DM2
Futuro en el tratamiento de la DM2
 
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
 
Nutrition therapy work shop dawly first part 2017
Nutrition therapy work shop dawly   first part  2017Nutrition therapy work shop dawly   first part  2017
Nutrition therapy work shop dawly first part 2017
 
Strive Teleconf Presentation Oct11 2006
Strive Teleconf Presentation Oct11 2006Strive Teleconf Presentation Oct11 2006
Strive Teleconf Presentation Oct11 2006
 
Ueda2015 sanofi insulin therapy dr.khaled el-hadidy
Ueda2015 sanofi insulin therapy dr.khaled el-hadidyUeda2015 sanofi insulin therapy dr.khaled el-hadidy
Ueda2015 sanofi insulin therapy dr.khaled el-hadidy
 
Updates of Diabetes Management 2020- Dr Shahjada Selim
Updates of Diabetes Management 2020- Dr Shahjada SelimUpdates of Diabetes Management 2020- Dr Shahjada Selim
Updates of Diabetes Management 2020- Dr Shahjada Selim
 
Diabetes atlas key headlines 2012
Diabetes atlas   key headlines 2012Diabetes atlas   key headlines 2012
Diabetes atlas key headlines 2012
 
Public heath challenges for NCDs, UHC and cost effective treatment, MySPOR 2014
Public heath challenges for NCDs, UHC and cost effective treatment, MySPOR 2014Public heath challenges for NCDs, UHC and cost effective treatment, MySPOR 2014
Public heath challenges for NCDs, UHC and cost effective treatment, MySPOR 2014
 
Improved Outcomes from Diabetes Outreach Programs in Rural and Remote Aborigi...
Improved Outcomes from Diabetes Outreach Programs in Rural and Remote Aborigi...Improved Outcomes from Diabetes Outreach Programs in Rural and Remote Aborigi...
Improved Outcomes from Diabetes Outreach Programs in Rural and Remote Aborigi...
 
ueda2012 cost effective diabetes treatment-d.edwin
ueda2012 cost effective diabetes treatment-d.edwinueda2012 cost effective diabetes treatment-d.edwin
ueda2012 cost effective diabetes treatment-d.edwin
 
Materi Workshop Diabetes Melitus untuk Dokter Umum - Practical Management of ...
Materi Workshop Diabetes Melitus untuk Dokter Umum - Practical Management of ...Materi Workshop Diabetes Melitus untuk Dokter Umum - Practical Management of ...
Materi Workshop Diabetes Melitus untuk Dokter Umum - Practical Management of ...
 
Clinical Improvement Proceeds Glycemic Homeostasis After Duodenal-jejunal Byp...
Clinical Improvement Proceeds Glycemic Homeostasis After Duodenal-jejunal Byp...Clinical Improvement Proceeds Glycemic Homeostasis After Duodenal-jejunal Byp...
Clinical Improvement Proceeds Glycemic Homeostasis After Duodenal-jejunal Byp...
 
Prof-Dennis-Yue-Kellion-Lecture.ppt
Prof-Dennis-Yue-Kellion-Lecture.pptProf-Dennis-Yue-Kellion-Lecture.ppt
Prof-Dennis-Yue-Kellion-Lecture.ppt
 
Renal disease in diabetes from prediabetes to late vasculopathy complication...
Renal disease in diabetes from prediabetes  to late vasculopathy complication...Renal disease in diabetes from prediabetes  to late vasculopathy complication...
Renal disease in diabetes from prediabetes to late vasculopathy complication...
 
What Spine Surgeons Need to Know About Dietary Strategies for Heart Disease a...
What Spine Surgeons Need to Know About Dietary Strategies for Heart Disease a...What Spine Surgeons Need to Know About Dietary Strategies for Heart Disease a...
What Spine Surgeons Need to Know About Dietary Strategies for Heart Disease a...
 
Resiko metabolik
Resiko metabolik Resiko metabolik
Resiko metabolik
 
Modern therapy in diabetics with cad scintic day
Modern therapy in diabetics  with cad scintic dayModern therapy in diabetics  with cad scintic day
Modern therapy in diabetics with cad scintic day
 

More from Lionel Wolberger

Fueling-the-AI-revolution.pdf
Fueling-the-AI-revolution.pdfFueling-the-AI-revolution.pdf
Fueling-the-AI-revolution.pdf
Lionel Wolberger
 
World Trade Center Collapse
World Trade Center CollapseWorld Trade Center Collapse
World Trade Center Collapse
Lionel Wolberger
 
Unique Properties At The Nanoscale
Unique Properties At The NanoscaleUnique Properties At The Nanoscale
Unique Properties At The Nanoscale
Lionel Wolberger
 
The Chemistry Of The Cell
The Chemistry Of The CellThe Chemistry Of The Cell
The Chemistry Of The Cell
Lionel Wolberger
 
You See It – But Do You Believe It
You See It – But Do You Believe ItYou See It – But Do You Believe It
You See It – But Do You Believe It
Lionel Wolberger
 
Clay Minerals And Soil Structure
Clay Minerals And Soil StructureClay Minerals And Soil Structure
Clay Minerals And Soil Structure
Lionel Wolberger
 
The Shapes Of Molecules
The Shapes Of MoleculesThe Shapes Of Molecules
The Shapes Of Molecules
Lionel Wolberger
 
Industrial Revolution
Industrial RevolutionIndustrial Revolution
Industrial Revolution
Lionel Wolberger
 
Wireless Broadband
Wireless BroadbandWireless Broadband
Wireless Broadband
Lionel Wolberger
 
Fundamental Elements Of Music
Fundamental Elements Of MusicFundamental Elements Of Music
Fundamental Elements Of Music
Lionel Wolberger
 
Donkey Milk
Donkey MilkDonkey Milk
Donkey Milk
Lionel Wolberger
 
Proteins – Basics you need to know for Proteomics
Proteins – Basics you need to know for ProteomicsProteins – Basics you need to know for Proteomics
Proteins – Basics you need to know for Proteomics
Lionel Wolberger
 
Vital Water
Vital WaterVital Water
Vital Water
Lionel Wolberger
 
Liquids and Solids
Liquids and SolidsLiquids and Solids
Liquids and Solids
Lionel Wolberger
 
The synaptic order a key concept to understand multicenter bonding synaptic
The synaptic order a key concept  to understand multicenter bonding synapticThe synaptic order a key concept  to understand multicenter bonding synaptic
The synaptic order a key concept to understand multicenter bonding synaptic
Lionel Wolberger
 
Introduction to Immunity Antibody Function & Diversity 2006 L1&2-overview & Ab
Introduction to Immunity Antibody Function & Diversity 2006 L1&2-overview & AbIntroduction to Immunity Antibody Function & Diversity 2006 L1&2-overview & Ab
Introduction to Immunity Antibody Function & Diversity 2006 L1&2-overview & Ab
Lionel Wolberger
 
Living Systems. eukaryotes. best pix. figures1.ppt
Living Systems. eukaryotes. best pix. figures1.pptLiving Systems. eukaryotes. best pix. figures1.ppt
Living Systems. eukaryotes. best pix. figures1.ppt
Lionel Wolberger
 
Autoimmunity
AutoimmunityAutoimmunity
Autoimmunity
Lionel Wolberger
 
Milky Way physics 101
Milky Way physics 101Milky Way physics 101
Milky Way physics 101
Lionel Wolberger
 

More from Lionel Wolberger (20)

Fueling-the-AI-revolution.pdf
Fueling-the-AI-revolution.pdfFueling-the-AI-revolution.pdf
Fueling-the-AI-revolution.pdf
 
World Trade Center Collapse
World Trade Center CollapseWorld Trade Center Collapse
World Trade Center Collapse
 
Unique Properties At The Nanoscale
Unique Properties At The NanoscaleUnique Properties At The Nanoscale
Unique Properties At The Nanoscale
 
The Chemistry Of The Cell
The Chemistry Of The CellThe Chemistry Of The Cell
The Chemistry Of The Cell
 
You See It – But Do You Believe It
You See It – But Do You Believe ItYou See It – But Do You Believe It
You See It – But Do You Believe It
 
Clay Minerals And Soil Structure
Clay Minerals And Soil StructureClay Minerals And Soil Structure
Clay Minerals And Soil Structure
 
The Shapes Of Molecules
The Shapes Of MoleculesThe Shapes Of Molecules
The Shapes Of Molecules
 
Industrial Revolution
Industrial RevolutionIndustrial Revolution
Industrial Revolution
 
Wireless Broadband
Wireless BroadbandWireless Broadband
Wireless Broadband
 
Fundamental Elements Of Music
Fundamental Elements Of MusicFundamental Elements Of Music
Fundamental Elements Of Music
 
Donkey Milk
Donkey MilkDonkey Milk
Donkey Milk
 
Proteins – Basics you need to know for Proteomics
Proteins – Basics you need to know for ProteomicsProteins – Basics you need to know for Proteomics
Proteins – Basics you need to know for Proteomics
 
Vital Water
Vital WaterVital Water
Vital Water
 
moon, mars, venus
moon, mars, venusmoon, mars, venus
moon, mars, venus
 
Liquids and Solids
Liquids and SolidsLiquids and Solids
Liquids and Solids
 
The synaptic order a key concept to understand multicenter bonding synaptic
The synaptic order a key concept  to understand multicenter bonding synapticThe synaptic order a key concept  to understand multicenter bonding synaptic
The synaptic order a key concept to understand multicenter bonding synaptic
 
Introduction to Immunity Antibody Function & Diversity 2006 L1&2-overview & Ab
Introduction to Immunity Antibody Function & Diversity 2006 L1&2-overview & AbIntroduction to Immunity Antibody Function & Diversity 2006 L1&2-overview & Ab
Introduction to Immunity Antibody Function & Diversity 2006 L1&2-overview & Ab
 
Living Systems. eukaryotes. best pix. figures1.ppt
Living Systems. eukaryotes. best pix. figures1.pptLiving Systems. eukaryotes. best pix. figures1.ppt
Living Systems. eukaryotes. best pix. figures1.ppt
 
Autoimmunity
AutoimmunityAutoimmunity
Autoimmunity
 
Milky Way physics 101
Milky Way physics 101Milky Way physics 101
Milky Way physics 101
 

Recently uploaded

ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
Catherine Liao
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
jval Landero
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
rebeccabio
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
Jim Jacob Roy
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 

Recently uploaded (20)

ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
The POPPY STUDY (Preconception to post-partum cardiovascular function in prim...
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in StockFactory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfMANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdf
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 

Managing Type 2 Diabetes

  • 1. Interventions to Improve Quality of Care Luigi Meneghini, MD, MBA Diabetes Research Institute (DRI) University of Miami School of Medicine II PAHO-DOTA Workshop on Quality of Diabetes Care DRI, 14–16 May 2003
  • 2.
  • 3.
  • 4.
  • 5. Mastering Your Diabetes Metabolic & Psychosocial Outcomes Diabetes Empowerment Scale (DES) The DES is a valid and reliable survey of patient empowerment which yields an overall empowerment score based on all 28 items and three subscale scores (range for all scales: 1.0-5.0). Improvement was evident on all DES scales for participants in the MYD pilot study, despite high baseline values. Diabetes Empowerment Scale Pretest Posttest 3mF/U Overall empowerment 4.1 4.2 4.3* Managing psychosocial aspects 3.9 4.2 4.2 Dissatisfaction/readiness to change 4.3 4.5 4.6* Setting/ achieving diabetes goals 4.0 4.0 4.1 (*P<0.05 v. baseline) Quality of Life & Self-Efficacy Measures of both Quality of Life (QOL) and Self-Efficacy showed statistically significant improvement following the intervention. At the three month follow-up the most significant improvement in QOL sub-scales was for Satisfaction (p=0.0113). 8.84 8.01 7.65 8.10 7.50 6.80 7.00 7.20 7.40 7.60 7.80 8.00 8.20 8.40 8.60 8.80 Mean HbA1c % Mo 1-3 Pre-MYD * p<0.05 v. pre-MYD Mo 4-6 Mo 7-9 Mo 10-12 * * *
  • 6. Healthcare Costs Increase With Worsening Glycemic Control *In patients with Type 2 diabetes alone (no cardiovascular complications). Increase in medical costs associated with rising HbA 1c levels compared to costs for patients with HbA 1c of 6%* 3-Year Medical Costs, 1993–1995 ($) 12,000 10,000 9,000 8,000 6 7 8 9 10 Baseline HbA 1c (%), 1992 5% 11% 21% 36% 11,000 Source: Gilmer TP et al. Diabetes Care 1997; 20: 1847-1853.
  • 7. Increase of Diabetes & Gestational Diabetes in the USA
  • 8. Global Projections of Diabetes (in millions, 1995-2010) 13.0 17.5 35% 12.4 22.5 81% 22.0 32.9 50% 0.9 1.3 44% 7.3 14.1 93% World 1995 = 118 million 2010 = 221 million Increase of 87% 62.8 132.3 111%
  • 9. Diabetes Mellitus in the USA: Health Impact of the Disease Diabetes Blindness* Kidney failure* Amputation* Life expectancy reduced by 5–10 years Heart disease ­ 2X to 4X *Diabetes is the #1 cause of renal failure, new cases of blindness, and non-traumatic amputations. Nerve damage in 60% to 70% of patients 6th leading cause of death Sources: Diabetes Statistics . October 1995 (updated 1997). NIDDK publication NIH 96-3926. Harris, MI. In: Diabetes in America ( 2nd ed.) 1995: 1-13.
  • 10. The Cost of Diabetes Diabetes costs the United States ~$132 billion annually! Total = $91.8 Billion Total = $39.8 Billion Source: American Diabetes Association. Diabetes Care 2003; 26: 917-932. $44.1 $23.2 $24.6 Direct Medical Expenses General Medical Conditions Diabetes & Acute Metabolic Complications Chronic Diabetes Complications Indirect Medical Expenses $21.6 $7.5 $10.8 Mortality Lost work days Restricted activity Permanent disability
  • 11. Projected Costs of Diabetes (USA, in billions) $200 $100 $0 1997 2002 2010 2020 $98 $192 $156 $132
  • 12.
  • 13.
  • 14.
  • 15.  
  • 16. NCQA/ADA Diabetes Physician Recognition Program 
  • 17. NCQA/ADA Diabetes Physician Recognition Program 
  • 18. Recognized Physicians Provide High-Quality Care Physicians achieving Recognition through the NCQA/ADA Diabetes Provider Recognition Program (DPRP) % of patients with Diabetes Provider Recognition Program, average performance of applicants, 2001 data. Health plan average, 2000 average performance data for plans, as reported in NCQA’s The State of Managed Care Quality - 2001 report, pp. 46 - 47. Medicare, 1998-99 fee-for-service data for the median state, JAMA,10/4/00 , Vol. 284, No. 13, p. 1674. * Lower is better for this measure.
  • 19.
  • 20. Short-Term Economic Impact of Managing Diabetes Is there a financial incentive for insurance plans and governments?
  • 21. Incremental Cost/QALY Gained When Compared to Standard Care Source: Leroith (ed.) Diabetes Mellitus , 1996, pp. 621-630.
  • 22.
  • 23. Yearly Costs of Care for Members with and without Diabetes Source: Selby JV. Diabetes Care 1997; 9: 1396.
  • 24. Excess Cost of Care for Diabetes (by site of care) Source: Selby JV. Diabetes Care 1997; 9: 1396.
  • 25. Standardized Cost Differential for 1% Change in HbA1c Source: Gilmer TP et al. Diabetes Care 1997;20:1847-1853.
  • 26.
  • 27. Impact of Comprehensive Diabetes Management Program Source: Rubin RJ, et al. J Clin Endocrinol Metab 1998; 83: 2635. * Total costs decreased by $44 per member/month (10.9%) which would translate into savings of $528,000 in the first year for a plan with 1000 members with diabetes. Break-even at 1,265 members with diabetes as per DTCA. $406 $362 $182 $135 $84 $76 $44 $45 $66 $76 $29 $30 $0 $50 $100 $150 $200 $250 $300 $350 $400 $450 Average Cost per member/month Total Inpatient Outpatient MD Drugs Other Baseline (54,186 member months) Follow-up (55,879 member months)
  • 28. Approach to Insulin-Requiring Patients with Type 2 Diabetes
  • 29.
  • 30. Identifying the Glycemic Burden Fasting Pre-prandial Post-prandial Hepatic Glucose Output Glucose Disposal Prandial Insulin Secretion
  • 31.
  • 32. Physiology of Insulin Secretion Muscle Gut Liver Hepatic Glucose Output Intestinal CHO Absorption Plasma Glucose Basal insulin Bolus Insulin (-) Pancreas
  • 33. 4:00 25 50 75 16:00 20:00 24:00 4:00 Plasma Insulin µ U/ml) 8:00 12:00 8:00 Time Near-Physiologic Insulin Replacement Lispro Aspart Regular Ultralente Glargine CSII Prandial replacement Basal Replacement
  • 34. Translating the Basal/Bolus Prescription PCP Carbohydrate counting Correction (supplemental) scale Insulin algorithms Insulin administration Glucose monitoring Psychosocial issues Special situation adjustments Diabetes Overview Knowledge & skills assessment Prandial insulin coverage Insulin Prescription Lantus 20 u HS CHO ratio 1/10 Correction ratio 1/40 BG target 120 mg/dl ?
  • 35. Components of the Diabetes Team The Ideal Scenario Dietitian Endocrinologist Nurse Educator Exercise Therapist Case Manager PCP         
  • 36.  
  • 37.
  • 38. The End                                      
  • 39.
  • 40.
  • 41.